Projet de loi portant des dispositions diverses en matière de spécialités pharmaceutiques, garde des pharmaciens et des mesures prophylactiques en matière de poliomyélite.
General information ¶
- Authors
-
CD&V
Els
Van Hoof
MR Damien Thiéry
Open Vld Dirk Janssens - Submission date
- Jan. 31, 2019
- Official page
- Visit
- Status
- Adopted
- Requirement
- Simple
- Subjects
- pharmacist medicinal product health policy health care infectious disease disease prevention medical institution health insurance
Voting ¶
- Voted to adopt
- Groen CD&V Vooruit Ecolo LE PS | SP DéFI ∉ Open Vld N-VA MR PVDA | PTB PP VB
Contact form ¶
Do you have a question or request regarding this proposition? Select the most appropriate option for your request and I will get back to you shortly.
Discussion ¶
March 28, 2019 | Plenary session (Chamber of representatives)
Full source
Rapporteur Benoît Piedboeuf ⚙
I would like to refer to my written report.
Damien Thiéry MR ⚙
Mr. Speaker, Mrs. Minister, dear colleagues, I would like to speak more specifically about the measure in favour of pharmacists’ guardianship, because it represents a great step forward.
The law proposal introduces a availability fee for pharmacists who participate in organized custody services. It will not be charged to patients, but to the INAMI. This is the importance of this text. Once the law comes into force, pharmacists will no longer charge supplements to patients for medications prescribed by a doctor, whether refundable or non-refundable. Until now, they could pay up to five euros of foreclosure. In short, once again, the patient’s interest is taken into account. This is a win-win situation.
These provisions are also positive for pharmacists, who are valued in their role and work. In addition, patients will no longer have to pay when they go to the guardianship pharmacy, if their doctor – as I have indicated – has prescribed them the drug.
The availability fee was estimated at around 65 euros. This amount, calculated with the sector on the basis of an average, satisfies the interested parties. This reform has been the subject of negotiations and was, in fact, long awaited. It will reduce costs for the patient and improve accessibility. We can only rejoice. This long-awaited event is finally here!
Other measures relating to pharmaceutical specialties and prophylactic provisions relating to poliomyelitis are more technical, but are also important. On these points, I refer to the discussions we had in the committee and which were, once again, very constructive.